Tag Archive: vildagliptin



To compare the incidence of hypoglycaemic events (HEs) in a real-world setting in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.


We performed a ≤16-week prospective, non-interventional, two-cohort study. Data were collected 1-6 weeks before and ≤6 weeks after fasting. Patients were enrolled who had been receiving vildagliptin (50 mg twice daily) or sulphonylurea (SU) as add-on to metformin at least 4 weeks prior to fasting.


The primary efficacy endpoint was incidence of HEs during the Ramadan fast. Changes in glycated haemoglobin (HbA(1c)) and body weight, as well as adherence to treatment, were also assessed.


Seventy-two patients were enrolled (vildagliptin, n = 30; SU, n = 41; no treatment, n = 1), of whom 23 (76.7%) and 36 (87.8%), respectively, completed the study. With vildagliptin, there were no HEs or severe HEs, compared with 34 HEs (15 patients, 41.7%) and one severe (grade 2) HE with SU. The mean between-group difference in the proportion who experienced at least one HE was -41.7% (95%CI -57.8%, -25.6%), p = 0.0002. Vildagliptin lowered mean HbA(1c) from 7.6% (SD 0.9%) at baseline to 7.2% (SD 0.7%) post-Ramadan, whereas SU had no effect (7.2% [SD 0.6%] vs 7.3% [SD 0.7%]; mean between-group difference -0.5% [95% CI -0.9%, -0.1%], p = 0.0262). The mean number of missed doses was markedly lower with vildagliptin (0.2 [SD 0.8] vs 7.6 [SD 14.9]; mean between-group difference -7.4 [95% CI -13.7, -1.20] doses; p = 0.0204). Body weight remained unchanged in both groups.


Vildagliptin caused no hypoglycaemia, was well adhered to and improved HbA(1c), making it a suitable treatment option for managing fasting. Study limitations are the sample size and the lack of diet and exercise data. When extrapolated to the global Muslim population with a similar clinical background, these findings could have considerable public health and clinical implications.


article taken from glucagon.com

As DPP-4 inhibitors are used to treat patients with type 2 diabetes, it is important to consider whether and how modulation of DPP-4 activity might affect the biology of the heart and blood vessels.

The effects of sitagliptin on hemodynamics in human subjects with ischemic heart disease have been examined in a study of 14 patients with stable CAD subjected to dobutamine stress echocardiography (DSE). Patients were administered an oral glucose challenge, with or without a single administration of sitagliptin 100 mg. Sitagliptin-treated subjects exhibited a significant increase in ejection fraction, and enhanced LV regional wall motion, with improved contractile velocity in ischemic segments. DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients with Coronary Artery Disease Circ Cardiovasc Imaging. 2010 2010 Mar;3(2):195-201 

Sauve et al examined the cardiovascular consequences of LAD ligation in normoglycemic Dpp4-/- mice, and in diabetic WT mice treated with sitagliptin or metformin. DPP4-/- hearts from normoglycemic mice exhibited increased basal expression of cardioprotective genes and proteins and Dpp4-/- mice exhibited normal cardiac structure and function yet significantly increased survival after LAD ligation. Treatment of diabetic WT mice with metformin or sitagliptin produced significant improvements in survival following LAD ligation. The cardioprotective effects of sitagliptin on ischemic myocardium are likely to be indirect, as sitagliptin did not improve functional recovery in ischemic murine hearts studied ex vivo, however administration of sitagliptin to mice for 24 hrs prior to experimental ischemia significantly improved LV function in isolated murine hearts studied ex vivo. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes following myocardial infarction in mice Diabetes 2010 Apr;59(4):1063-73

Ye and colleagues compared the effects of sitagliptin and pioglitazone on infarct size and signal transduction in rodent models of ischemia. Treatment of mice with sitagliptin or pioglitazone for 3  or 14 days reduced infarct size using an in vivo model of ischemia re-perfusion injury. Sitagliptin increased cardiac levels of cAMP, and infusion of the PKA inhibitor attenuate the cardioprotective actions of sitagliptin but not pioglitazone. Pioglitazone and sitagliptin exerted different effects on cPLA2 and Cox2 activity, and both agents increased eNOS and CREB phosphorylation. Sitagliptin alone had no effect in isolated cardiomyocytes, whereas sitagliptin plus exogenous GLP-1 reduced cardiomyocyte injury in a cellular model of simulated ischemia-reperfusion injury The myocardial infarct size limiting effects of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010 298(5):H1454-65

Contrasting results were obtained in studies by Yin and colleagues in male Sprague Dawley non-diabetic rats (n= 8-10 rat per group) with LAD ligation that were either pretreated with vildagliptin (15 mg/kg/day) for 2 days, or vildagliptin was commenced 3 weeks after LAD ligation, and continued for another 9 weeks. Cardiovascular function was assessed in the chronic treatment group by Echo and invasive hemodynamics. Active levels of GLP-1 were significantly increased and DPP-4 activity was reduced by 70% in vildagliptin-treated rats. Infarct size trended lower in vildagliptin-treated rats. Cardiac capillary density was lower after MI and not affected by vildagliptin. Cadiomyocyte size was higher after MI but not significantly different with vildagliptin; similarly vildagliptin did not reverse the extent of LV hypertrophy. After MI, all rats exhibited LV dilation and systolic dysfunction, findings not changed by vildagliptin treatment. No significant differences in cardiomyocyte gene expression were reported. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure Cardiovasc Diabetol. 2011 Sep 28;10(1):85

Gomez and colleagues examined the effects of sitagliptin therapy in a pacing-induced model of heart failure in normoglycemic pigs. Sitagliptin was administered for 3 weeks, commencing 1 week after initiation of rapid pacing. Sitagliptin-treated pigs exhibited increased heart rate, yet increased stroke volume and preservation of GFR. Sitagliptin did not attenuate LV dilation. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure Eur J Heart Fail. 2011 Nov 1.

GLP-1(9-36): A DPP-4 generated metabolite and cardioactive peptide

Unexpectedly, both GLP-1 and GLP-1(9-36) amide  were found to improve left ventricular functioning in dogs with pacing-induced dilated cardiomyopathy (DCM) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2401-8.  DCM was induced by rapid right ventricular pacing for 28 days. Rapid pacing was suspended, and dogs either received a 48-hour iv infusion of GLP-1 (1.5 pmol/kg/min, n=9), GLP-1(9-36) (1.5 pmol/kg/min, n=7), or saline control. Both GLP-1 and GLP-1(9-36) significantly reduced LVEDP, and increased the first derivative of LV pressure. These improvements were nearly identical with each form of peptide. Both GLP-1 and GLP-1(9-36) significantly improved LV stroke volume, LVEF, and cardiac output to a comparable degree. GLP-1(9-36) also reduced ischemic damage following ischemia/reperfusion injury in the isolated mouse heart. Twenty minutes of GLP-1(9-36) (0.3 nM) treatment, administered immediately following ischemia during the reperfusion phase, significantly improved functional recovery of the left ventricle in wild-type and unexpectedly, in hearts from Glp1r-/- mice. GLP-1(9-36) (0.3 nM) also increased cGMP release measured from coronary effluent samples taken at various time points from normoxic perfused hearts of wild-type and Glp1r-/- mice. Both GLP-1 and GLP-1(9-36) induced vasodilation and significantly increased coronary flow to the same magnitude. The addition of sitagliptin (5 μM) to GLP-1-treated mesenteric arteries reduced, but did not abolish, the vasodilatory response to GLP-1. This suggests that both GLP-1 and the metabolite GLP-1(9-36) have vasodilatory actions. Consistent with this observation, both GLP-1 and GLP-1(9-36) elicited vasodilation in arteries from Glp1r-/- mice Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation. 2008 May 6;117(18):2340-50


Stromal cell-derived factor-1 (SDF-1)

SDF-1 is an endogenous DPP-4 substrate. Plasma from Dpp4-/- mice contains exclusively C-terminally truncated SDF-1, whereas SDF-1 was degraded at both the C- and N-terminus in wild-type mice Circulating CD26 is negatively associated with inflammation in human and experimental arthritis Am J Pathol. 2005 Feb;166(2):433-42 . Preclinical data indicates that SDF-1 expression is upregulated in the ischemic myocardium in mice immediately following infarction Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury Circulation. 2004 Nov 23;110(21):3300-5 , and myocardial SDF-1 gene transfer increases the mobilization and homing of stem cells toward ischemic myocardium, leading to neovascularization and enhanced post-infarction recovery in rats and mice Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy Lancet. 2003 Aug 30;362(9385):697-703  and Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1alpha (SDF-1alpha) treatment. Regul Pept. 2005 Feb 15;125(1-3):1-8

SDF-1 has been shown to protect against deterioration of cardiac function in mice after acute myocardial infarction via angiogenesis promotion Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction Circulation. 2008 Apr 29;117(17):2224-31. The essential role of SDF-1 in the recruitment of stem and progenitor cells toward the ischemic/hypoxic myocardium is through its cognate receptor, CXC chemokine receptor 4 (CXCR4). Zaruba et al. utilized a model of combined genetic or pharmacologic inhibition of DPP-4 with granulocyte- colony stimulating factor (G-CSF)-mediated stem cell mobilization after MI in mice. This approach lead to increased myocardial homing of circulating CXCR4+ stem-cells, reduced cardiac remodeling, and improved heart function and survival. Dpp4-/- mouse myocardium showed no DPP-4 activity 2 days post-MI, with low levels of DPP-4 activity in serum. Use of the DPP-4 inhibitor Diprotin-A in combination with G-CSF (100 μg/kg/day ip), lead to decreased DPP-4 activity following MI in the myocardium but not in serum of wild-type mice. Flow cytometry analyses of heart tissue 48h after MI revealed that both genetic and pharmacological inhibition of DPP-4 in combination with G-CSF resulted in significantly increased recruitment of CD45+/CD34+/c-kit+, CD45+/CD34+/Sca-1+, CD45+/CD34+/CXCR4+, and CD45+/CD34+/Flk-1+ progenitor cells as well as lin-c-kit+Sca-1+ hematopoietic stem cells into ischemic myocardium. This effect was reversed when these mice were treated with the CXCR4 antagonist AMD3100 (ip,1.25 mg/kg). Loss or inhibition of DPP-4 function in combination with G-CSF treatment reduced scar tissue and apoptosis and ameliorated thickness of the LV wall 30 days post-MI, as analyzed by histology. Finally, G-CSF administration in Dpp4-/- mice, or Diprotin-A-treated wild-type mice improved survival, as well as LVEF, cardiac output, and contractility Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction Cell Stem Cell. 2009 Apr 3;4(4):313-23.

As SDF-1 is an essential DPP-4 substrate that mobilizes endothelial progenitor cells to sites of vascular or myocardial injury, the finding that sitagliptin treatment of subjects with T2DM also results in an increase in circulating endothelial progenitor cells is intriguing The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes mellitus. Possible role of stromal derived factor-1{alpha} Diabetes Care. 2010 Mar 31. [Epub ahead of print]

The SITAGRAMI-Trial (Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction). Based on the results of preclinical studies, a randomized clinical trial is underway in human subjects with myocardial infarction and successful PCI who then receive a 5 day treatment of G-CSF and 28 days of sitagliptin.The primary study outcome is change in global myocardial function after 6 months, taken to be an indirect reflection of cardiac regeneration. Interim safety analysis of the first 36 patients did not raise any concerns as outlined in Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) – Rationale, design and first interim analysis. Int J Cardiol. 2010 Jan 3. [Epub ahead of print]

Other hormones that exert their actions through GPCRs also may reduce infarct size after experimental MI in mice through related mechanisms, namely enhanced SDF-1-directed stem cell mobilization and repair of injured myocardial tissue through the SDF-1:Cxcr4 axis. For example parathyroid hormone (PTH) administration to mice after LAD ligation and experimental MI improves survival in association with enhanced number of bone marrow-derived cells in the injured heart Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival Cardiovasc Res. 2008 Mar 1;77(4):722-31. Surprisngly, PTH also inhibits the activity of DPP-4 both in vitro and in mice after exogenous PTH administration. Hence, the beneficial effects of PTH in the context of experimental MI may be linked to enhanced mobilization of CXCR4+ bone marrow cells to the injured myocardium, in part through direct effects of PTH on the bone marrow, and perhaps in part through DPP-4-mediated stabilization of SDF-1 Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4+ stem cells into the ischemic heart Cardiovasc Res. 2011 Jan 18.


BNP is a peptide hormone synthesized in the heart and is a major contributor in the regulation of cardiovascular homeostasis, mediating vasodilation, lusitropism, natriuresis, and supression of renin secretion. The physiological concentration of BNP in plasma noticeably increases in patients with cardiac overload. Therefore, BNP has largely been used in a clinical setting as a prognostic marker for patients with cardiac hypertrophy and heart failure. DPP-4 removes the two NH2-terminal amino acids of BNP to produce BNP(3-32) Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form Clin Chem. 2006 Jan;52(1):82-7. With respect to cardio-renal actions of BNP(3-32), this peptide has reduced renal actions when compared to full-length BNP, and lacks any vasodilating ability Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R897-901. The endogenous levels of BNP in Dpp4-/- mice and in mice and humans treated with a DPP-4 inhibitor are currently unknown, and the potential influence of BNP on cardiac remodeling and contractile dysfunction following MI requires further study.

Neuropeptide Y

Neuropeptide Y (NPY) is a 36 amino acid peptide, originally isolated from the porcine brain. NPY is primarily synthesized and released by neurons, and belongs to a family of neuroendocrine peptides. NPY is found colocalized with norepinephrine in all sympathetic nerves that innervate the cardiovascular system, and is the most abundant neuropeptide in the heart. Human coronary arteries in particular, are abundantly innervated with fibers containing NPY. The NPY receptor Y1 is the major vascular receptor in that it mediates vasoconstriction in small arteries of coronary and splanchnic vascular beds and arterial smooth muscle cell proliferation. In humans and animals, plasma NPY levels are increased in response to tissue injury and ischemia, and in a variety of conditions with sympathetic hyperactivity, such as hypertension and congestive heart failure.

Intact NPY(1-36) binds the Y1 receptor (Y1R ). Cleavage of NPY from a Y1R agonist to non-Y1 (a Y2/Y5 R ligand) is dependent on DPP-4 Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV Regul Pept. 1993 Dec 10;49(2):133-44. with NPY and DPP-4 being colocalized in blood vessels. DPP-4-cleaved NPY(3-36) is the second major circulating form of the peptide, and is capable of activation of all non-Y1 receptors, namely Y2, Y3 and Y5. These receptors are found not only in the central and peripheral nervous system , but also in blood vessels. DPP-4 conversion of NPY to NPY(3-36) is necessary for angiogenic activity, as the use of a DPP-4 neutralizing antibody resulted in the loss of NPY-mediated endothelial cell migration in an endothelial wound assay Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding Peptides. 2001 Mar;22(3):453-8.

A potential increase in circulating NPY as a result of reduced DPP-4 activity may have effects on blood pressure. Jackson et al. found that DPP-4 inhibition by sitagliptin augmented the ability of exogenous NPY(1-36) to enhance renovascular responses to angiotensin II (AngII) in kidneys from genetically hypertensive rats. Administration of Ang II (0.3 nmol/L) to isolated, perfused kidneys from adult spontaneously hypertensive rats (SHR) resulted in increased perfusion pressure, indicative of vasoconstriction, that was significantly enhanced when exogenous NPY(1-36) (6 nmol/L) was added to the perfusate. This effect was blocked when kidneys were pretreated for 20 minutes with 1 μM BIBP3226 (a highly selective Y1 receptor blocker), or the DPP-4 inhibitor sitagliptin (1 μM) Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension Hypertension. 2008 Jun;51(6):1637-42

Nevertheless, no problems with blood pressure have been detected in clinical trials examining the effects of DPP-4 inhibitors in diabetic subjecst. A short-term study in 19 non-diabetic, mild to moderately hypertensive patients revealed no effects of sitagliptin treatment (50 or 100 mg BID for 5 days) on 24-hour ambulatory blood pressure measurements Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008 May;48(5):592-8. The endogenous levels of NPY in Dpp4-/- mice and in mice treated with a DPP-4 inhibitor have not been reported, and the potential influence of NPY on coronary vasoconstriction is unknown.

Shah and colleagues used the DPP-4 inhibitos, alogliptin, to assess the direct consequences of DPP-4 inhibitoon on vascular tone of preconstricted aortic rings from C57BL/6 mice. Alogliptin produced a profound dose-dependent relaxation response that was not affected by the GLP-1R antagonist exendin(9-39), but was partially attenuated by denudation of the endothelium, or by pre-treatement with the NO synthase inhibitor LNMMA and the guanyl cyclase inhibitor ODQ. Combined inhibition of eNOS and K+ channel conductance with multiple inhibitors completely blocked the vasodilatory effect of alogliptin. Alogliptin also caused rapid release of NO from HUVEC cells, together with increased phsophorylation of NO and Akt. The vasodilatory effects of alogliptin were also reduced by the signal transduction inhibitors SH6, wortmannin, and PP2. The extent of inhibition achieved with alogliptin was not described Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways Vascul Pharmacol. 2011 Mar 9. [Epub ahead of print]

Ta and colleagues examined the effects of alogliptin on atherosclerosis development in normoglycemic and diabetic ApoE-/- mice. Male mice were placed on a 60% high fat diet, and at age 12 weeks, STZ was administered to induce diabetes in some mice. Four weeks later, several groups of mice were administered alogliptin 15 mg/kg via daily gavage. Diabetic mice lost weight and exhibited reduced insulin levels. Alogliptin therapy for 24 weeks improved glycemia (473 vs 349 mg/dl), and decreased levels of cholesterol and triglycerides. Intimal lesion area in the aorta was greater in diabetic mice; alogliptin therapy had no effect on lesion size in non-diabetic mice but did significantly reduce lesion size in diabetic mice. Immunohistochemical quantification revealed reduced IL-6 and IL-1b in the atherosclerotic placques of alogliptin-treated diabetic mice. Alogliptin also reduced IL-6 secretion and IL-6 expression in LPS-stimulated U937 cells. Gene expression studies demonstrated that alogliptin had broad actions to reduce cytokine expression in LPS-stimualted U937 mononuclear cells DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice J Cardiovasc Pharmacol. 2011 May 6. [Epub ahead of print]

The actions of alogliptin, and in some instances, sitagliptin, were also examined by Shah and colleagues, primarily in Ldlr-/- mice, with or without a high fat diet for 12 weeks. A number of salutary changes in inflammatory gene expression, cell migration, reduction of aortic plaque and reduced plaque inflammatory cell infiltration were noted in alogliptin-treated mice. Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis Circulation. 2011 Oct 17. [Epub ahead of print